CA2993312A1 - 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists - Google Patents

1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists Download PDF

Info

Publication number
CA2993312A1
CA2993312A1 CA2993312A CA2993312A CA2993312A1 CA 2993312 A1 CA2993312 A1 CA 2993312A1 CA 2993312 A CA2993312 A CA 2993312A CA 2993312 A CA2993312 A CA 2993312A CA 2993312 A1 CA2993312 A1 CA 2993312A1
Authority
CA
Canada
Prior art keywords
group
compound
atom
amino
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2993312A
Other languages
English (en)
French (fr)
Inventor
Dinesh Barawkar
Anil M. DESHPANDE
Santosh Patil
Yogesh Waman
Anil PANMAND
Dilip JADHAV
Bheemashankar Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2993312A1 publication Critical patent/CA2993312A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2993312A 2015-07-23 2016-07-22 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists Abandoned CA2993312A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2244DE2015 2015-07-23
IN2244/DEL/2015 2015-07-23
PCT/JP2016/072244 WO2017014323A1 (en) 2015-07-23 2016-07-22 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
CA2993312A1 true CA2993312A1 (en) 2017-01-26

Family

ID=56740432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2993312A Abandoned CA2993312A1 (en) 2015-07-23 2016-07-22 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists

Country Status (7)

Country Link
US (2) US10745397B2 (enExample)
EP (1) EP3325490B1 (enExample)
JP (1) JP6689297B2 (enExample)
CN (1) CN108368127B (enExample)
CA (1) CA2993312A1 (enExample)
DK (1) DK3325490T3 (enExample)
WO (1) WO2017014323A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
AU2018268311B2 (en) 2017-05-18 2022-02-10 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
MX394108B (es) 2017-05-18 2025-03-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos.
CN110612296A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的苯基衍生物
US20200352912A1 (en) * 2018-01-26 2020-11-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Antimicrobial compositions and methods of using the same
CN117643587A (zh) * 2018-02-05 2024-03-05 深圳市原力生命科学有限公司 用于治疗癌症的杂二环羧酸
JP7443357B2 (ja) 2018-10-23 2024-03-05 ビーエーエスエフ ソシエタス・ヨーロピア 三環式の殺有害生物化合物
EP3930845A1 (en) * 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN112094249B (zh) * 2019-06-17 2022-03-08 中国科学院苏州纳米技术与纳米仿生研究所 磺胺甲噻二唑-糖精共晶及其制备方法与应用
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
AU2021256876A1 (en) 2020-04-14 2022-11-03 Basf Se Tricyclic pesticidal compounds
EP3907214A1 (en) * 2020-05-04 2021-11-10 Dompe' Farmaceutici S.P.A. Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
EP1787991B2 (en) 2004-07-28 2020-06-24 Takeda Pharmaceutical Company Limited PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
JP5396379B2 (ja) * 2007-04-02 2014-01-22 エボテック・アーゲー ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用
EP2460787A1 (en) * 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
US8404736B2 (en) * 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
EP2375899B1 (en) 2009-01-12 2015-02-25 Array Biopharma Inc. Piperidine-containing compounds and use thereof in the treatment of diabetes
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016088903A1 (en) 2014-12-05 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Also Published As

Publication number Publication date
CN108368127A (zh) 2018-08-03
US20180215754A1 (en) 2018-08-02
WO2017014323A1 (en) 2017-01-26
JP2018527295A (ja) 2018-09-20
US10745397B2 (en) 2020-08-18
CN108368127B (zh) 2020-12-11
DK3325490T3 (da) 2020-02-03
EP3325490A1 (en) 2018-05-30
EP3325490B1 (en) 2019-12-18
US20200339577A1 (en) 2020-10-29
JP6689297B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
US20200339577A1 (en) 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
CN105899505B (zh) 用于治疗自身免疫病症的吡唑
US10081624B2 (en) Heterocyclic compound
AU2016297362B2 (en) Oxadiazole derivatives useful as HDAC inhibitors
WO2016021742A1 (en) Heterocyclic compounds as ep4 receptor antagonists
ES2605388T3 (es) Compuesto inhibidor de Trk
US10357484B2 (en) Heterocyclic compound
WO2016199943A1 (en) Heterocyclic compounds
JP5408434B2 (ja) アミド化合物
JPWO2016039408A1 (ja) 複素環化合物
CN106459040A (zh) 杂环化合物
WO2016088903A1 (en) Heterocyclic compounds
WO2014181813A1 (ja) 複素環化合物
WO2015146928A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210713

FZDE Discontinued

Effective date: 20240123